CD274 and neoplasm: Data of the phase II CITYSCAPE trial showed an ORR of 69.0% in the PD-L1 tumor proportion score (TPS) ≥ 50% group and 38.8% in the intention-to-treat group using tiragolumab and atezolizumab.